albuterol has been researched along with Multiple Sclerosis in 5 studies
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| " The dose-response relationship was similar within the non-asthma patients." | 1.40 | Beta2-adrenergic agonist use and the risk of multiple sclerosis: a total population-based case-control study. ( Lee, CT; Lin, FC; Tsai, CP, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Almeida, GM | 1 |
| Scola, RH | 1 |
| Ducci, RDP | 1 |
| Cirino, RHD | 1 |
| Cláudia, SKK | 1 |
| Lorenzoni, PJ | 1 |
| Lima, PHS | 1 |
| de Oliveira, LP | 1 |
| Werneck, LC | 1 |
| Tsai, CP | 1 |
| Lin, FC | 1 |
| Lee, CT | 1 |
| Axelrod, S | 1 |
| Bielory, L | 1 |
| Makhlouf, K | 2 |
| Comabella, M | 1 |
| Imitola, J | 1 |
| Weiner, HL | 2 |
| Khoury, SJ | 2 |
1 review available for albuterol and Multiple Sclerosis
| Article | Year |
|---|---|
Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol).
Topics: Adjuvants, Immunologic; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; An | 2002 |
1 trial available for albuterol and Multiple Sclerosis
| Article | Year |
|---|---|
Does oral salbutamol improve fatigue in multiple sclerosis? A pilot placebo-controlled study.
Topics: Adolescent; Adult; Aged; Albuterol; Brazil; Double-Blind Method; Fatigue; Humans; Middle Aged; Multi | 2020 |
3 other studies available for albuterol and Multiple Sclerosis
| Article | Year |
|---|---|
Beta2-adrenergic agonist use and the risk of multiple sclerosis: a total population-based case-control study.
Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Case-Control Studies; Child; Chil | 2014 |
Beta2-agonists and paresthesias in multiple sclerosis.
Topics: Adrenergic beta-Agonists; Albuterol; Amantadine; Analgesics, Non-Narcotic; Androstadienes; Aromatase | 2007 |
Oral salbutamol decreases IL-12 in patients with secondary progressive multiple sclerosis.
Topics: Administration, Oral; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; B7-1 Antigen; Buclades | 2001 |